Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
Triple therapy, including glucocorticoid at either of 2 dose levels, is beneficial for moderate-to-very severe chronic obstructive pulmonary disease.
Medication adherence for asthma and chronic obstructive pulmonary disease has increased during the COVID-19 pandemic,
In patients hospitalized for COPD exacerbation, the presence of atrial fibrillation may increase the risk of in-hospital mortality.
In patients with COPD and hypercapnia, the use of home noninvasive positive pressure ventilation compared with no device was significantly associated with improved clinical outcomes but no significant differences in quality of life.
Patients who are socioeconomically disadvantaged are more likely to continue smoking after a COPD diagnosis.
The addition of tiotropium does not reduce COPD exacerbations.
The number of patients receiving all recommending pharmacologic therapies improved after the implementation of a computerized multidisciplinary order in patients’ EHRs.
